HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Looks To Resume Unannounced Inspections In India And China

Executive Summary

After lapsing due to COVID-19, an unannounced foreign inspection pilot program is on track to resume in 2022, “despite challenges and constraints of travel.”

You may also be interested in...



US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions

HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.

US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.

India’s COVID-19 Surge Forced Another Abrupt Stop Of US FDA In-Person Inspections

Agency inspectors worked in the country for about a month before the coronavirus infection surge forced another halt.

Related Content

Topics

UsernamePublicRestriction

Register

RS152041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel